- Home
- CLSK vs IDYA Comparison
CLSK vs IDYA Comparison
Compare CLSK & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSK
- IDYA
- Stock Information
- Founded
- CLSK 1987
- IDYA 2015
- Country
- CLSK United States
- IDYA United States
- Employees
- CLSK N/A
- IDYA N/A
- Industry
- CLSK Finance: Consumer Services
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- CLSK Finance
- IDYA Health Care
- Exchange
- CLSK Nasdaq
- IDYA Nasdaq
- Market Cap
- CLSK 2.7B
- IDYA 2.2B
- IPO Year
- CLSK N/A
- IDYA 2019
- Fundamental
- Price
- CLSK $10.44
- IDYA $24.27
- Analyst Decision
- CLSK Strong Buy
- IDYA Strong Buy
- Analyst Count
- CLSK 9
- IDYA 13
- Target Price
- CLSK $20.91
- IDYA $51.36
- AVG Volume (30 Days)
- CLSK 24.3M
- IDYA 984.2K
- Earning Date
- CLSK 08-07-2025
- IDYA 08-08-2025
- Dividend Yield
- CLSK N/A
- IDYA N/A
- EPS Growth
- CLSK N/A
- IDYA N/A
- EPS
- CLSK N/A
- IDYA N/A
- Revenue
- CLSK $537,401,000.00
- IDYA $7,000,000.00
- Revenue This Year
- CLSK $103.35
- IDYA $115.83
- Revenue Next Year
- CLSK $41.57
- IDYA $252.50
- P/E Ratio
- CLSK N/A
- IDYA N/A
- Revenue Growth
- CLSK 89.47
- IDYA N/A
- 52 Week Low
- CLSK $6.45
- IDYA $13.45
- 52 Week High
- CLSK $17.97
- IDYA $44.04
- Technical
- Relative Strength Index (RSI)
- CLSK 38.81
- IDYA 59.26
- Support Level
- CLSK $11.18
- IDYA $24.46
- Resistance Level
- CLSK $12.17
- IDYA $26.16
- Average True Range (ATR)
- CLSK 0.73
- IDYA 1.15
- MACD
- CLSK -0.30
- IDYA 0.14
- Stochastic Oscillator
- CLSK 6.27
- IDYA 60.87
About CLSK CleanSpark Inc.
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.